How India Exports Pioglitazone to the World

In the United States, pioglitazone has been approved through the Abbreviated New Drug Application (ANDA) pathway, allowing generic versions to enter the market. The FDA's Orange Book lists multiple approved ANDAs for pioglitazone, indicating a competitive generic landscape. Notably, there have been no recent import alerts or significant regulatory actions affecting pioglitazone imports from India. This stable regulatory environment has facilitated consistent exports from India, with 115 active exporters contributing to the U.S. market.

In the European Union, pioglitazone has been subject to various regulatory actions. For instance, the marketing authorization for Glidipion (pioglitazone) was withdrawn on 19 July 2021 at the request of the marketing authorization holder, Actavis Group PTC ehf, due to commercial reasons. Similarly, the marketing authorization for Glubrava (pioglitazone/metformin hydrochloride) was withdrawn on 24 May 2022 at the request of Takeda Pharma A/S. These withdrawals reflect commercial decisions rather than safety or efficacy concerns. Manufacturers exporting to the EU and UK must comply with Good Manufacturing Practice (GMP) standards as outlined by the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

Pioglitazone is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in global health. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, pioglitazone is classified under Schedule H, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set ceiling prices for pioglitazone formulations to ensure affordability; for example, the price for pioglitazone 15 mg tablets was capped in July 2025. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pioglitazone, ensuring compliance with national regulations.

The primary patents for pioglitazone have expired, leading to increased generic competition globally. This has resulted in a diversified market with multiple manufacturers producing generic versions, contributing to the substantial export figures from India.

In August 2025, the NPPA revised the ceiling price for pioglitazone 30 mg tablets, reducing it by 5% to enhance affordability. In October 2025, the FDA approved a new generic version of pioglitazone, further intensifying market competition. In December 2025, the EMA issued updated guidelines on the use of pioglitazone, emphasizing monitoring for potential adverse effects. In January 2026, the Indian government introduced new export incentives for pharmaceutical products, including pioglitazone, to boost international trade. In March 2026, the WHO updated its Essential Medicines List, reaffirming the inclusion of pioglitazone for the treatment of type 2 diabetes.

These developments reflect the dynamic regulatory and market landscape for pioglitazone, influencing both domestic policies and international trade.

India's pharmaceutical industry, while robust in manufacturing finished formulations, heavily relies on imports for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 60–70% of these essential components are sourced from China. This dependency poses a significant risk, as any disruption in the supply chain from China—be it due to geopolitical tensions, trade restrictions, or production issues—can adversely affect the availability and cost of APIs necessary for producing medications like pioglitazone.

In recent years, efforts have been made to reduce this dependency. The Indian government's Production Linked Incentive (PLI) scheme, initiated in 2021, aims to bolster domestic production of critical APIs and KSMs. However, as of March 2026, the impact of this initiative on reducing import reliance remains limited, and the industry continues to be vulnerable to external supply chain disruptions.

The export market for pioglitazone is notably concentrated. The top five exporters—led by AUROBINDO PHARMA LTD with a 40.7% share—collectively account for 74.2% of the total export value. Such concentration increases the risk of supply disruptions. If any of these key suppliers face operational challenges, regulatory issues, or other unforeseen events, the global supply of pioglitazone could be significantly impacted.

While the PLI scheme aims to diversify and strengthen the pharmaceutical manufacturing base in India, its effects on reducing supplier concentration in the pioglitazone market have yet to materialize substantially. The industry remains susceptible to risks associated with high supplier concentration.

Recent geopolitical events have further strained the pharmaceutical supply chain. In late February 2026, escalating tensions between the United States and Iran led to the closure of the Strait of Hormuz, a critical maritime chokepoint through which a significant portion of global oil and cargo shipments pass. This closure disrupted shipping routes, causing delays and increased transportation costs. Shipping companies have been forced to reroute vessels around the Cape of Good Hope, adding 10–14 days to transit times and incurring additional costs of up to $1 million per trip.

These disruptions have had a cascading effect on the global supply chain, including the pharmaceutical sector. Delays in the transportation of APIs and finished products can lead to shortages and increased prices, affecting both manufacturers and consumers.

To address the identified risks in the pioglitazone supply chain, the following actions are recommended:

• Diversify API and KSM Sources: Encourage and invest in the development of alternative sources for APIs and KSMs, both domestically and from other countries, to reduce reliance on a single nation.

• Strengthen Domestic Manufacturing: Accelerate the implementation and impact of the PLI scheme to enhance domestic production capabilities for critical pharmaceutical components.

• Expand Supplier Base: Promote the growth of small and medium-sized pharmaceutical manufacturers to reduce market concentration and mitigate single-source risks.

• Enhance Supply Chain Resilience: Develop contingency plans and establish alternative shipping routes to navigate geopolitical disruptions effectively.

• Monitor Geopolitical Developments: Maintain vigilant monitoring of international events that could impact supply chains and proactively adjust strategies to mitigate potential disruptions.

RISK_LEVEL: HIGH